A Translational in-vitro screening platform using Non-Human PrimateiPSC-derived ventricular cardiomyocytes Poster

This poster presents Ncardia’s non-human primate (NHP) iPSC-derived ventricular cardiomyocyte platform, developed for scalable, high-throughput functional screening and translational cardiac safety assessment. 

Download it now for a closer look at:

• How NHP iPSC-derived cardiomyocytes can be manufactured at scale while maintaining high purity, structural fidelity, and stable functional performance
  
• Comparative MEA and impedance assay data highlighting species-specific electrophysiological and contractile responses between human and NHP cardiomyocytes
• How acute and chronic drug exposure studies reveal differences in arrhythmia sensitivity, cytotoxicity, and contractility profiles across species
• Functional characterization data demonstrating robust responses to cardioactive compounds including nifedipine, dofetilide, quinidine, and sunitinib

• How this platform supports cross-species interpretation of screening and safety data in advanced discovery workflows